SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

PN-8047

PTGX·Protagonist Therapeutics, Inc
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical
Time to market
Preclinical stage with no disclosed IND timeline. If development proceeds, clinical trials would likely take several years, meaning potential approval is likely 5+ years away, if at all.
Why 2/10
PN-8047 is a preclinical asset with no scheduled hard catalyst (no IND, no clinical trial, no PDUFA date) within the next 12 months. It is one of several early-stage programs at a company whose value is driven by two approved products (ICOTYDE, MIMRYLO) and the more advanced PN-881 program. ImpactScore is 2: preclinical/minor program with nothing scheduled.
Actionable Insight NEUTRAL

PN-8047 has no near-term catalysts. The next meaningful pipeline catalyst for Protagonist is the Phase 2b initiation of PN-881 in early Q1 2027. Watch for any preclinical data disclosures or IND filing announcements for PN-8047 in future earnings calls or scientific conferences, but this program is unlikely to move the stock in the next 12 months.

Price Chart

Loading chart...

Executive Summary

PN-8047 is a preclinical-stage, wholly-owned oral hepcidin mimetic being developed by Protagonist Therapeutics (PTGX). It was first disclosed in the company's Q4 2025 earnings release in February 2026 as part of an expanded preclinical pipeline. PN-8047 is an oral follow-on to MIMRYLO (rusfertide), Protagonist's injectable hepcidin mimetic that received FDA approval in August 2026 for polycythemia vera. As a preclinical asset with no disclosed IND timeline, no clinical data, and no near-term catalysts, PN-8047 is a very early exploratory program. Protagonist's current market value is driven primarily by its two approved products (ICOTYDE for psoriasis and MIMRYLO for polycythemia vera) and its more advanced pipeline candidate PN-881 (Phase 1 completed, Phase 2b planned for early Q1 2027).

How It Works

PN-8047 is an oral hepcidin mimetic. Hepcidin is a hormone that controls how the body absorbs and uses iron. By mimicking hepcidin, the drug aims to reduce excess iron in the blood. This is an oral version of the same mechanism as Protagonist's already-approved injectable drug MIMRYLO (rusfertide), which treats polycythemia vera, a condition where the body makes too many red blood cells.

Trial Status

PN-8047 is in preclinical development. It was first disclosed in Protagonist's Q4 2025 earnings release in February 2026. No IND has been filed, no clinical trials have been initiated, and no clinical data have been reported. The program is part of Protagonist's wholly-owned preclinical pipeline alongside PN-477 (triple GLP-GIP-GCG agonist) and PN-458 (dual GLP-1/GIP receptor agonist).

The Two-Sided Case

▲ Bull Case3
PN-8047 is an oral hepcidin mimetic that could be a convenient oral follow-on to MIMRYLO (rusfertide), which is already FDA-approved and generating revenue. An oral version could expand the addressable patient population beyond those willing to take injections.
Protagonist has a strong balance sheet ($834.6M cash as of Q3 2026) and a $300M share repurchase program, providing ample funding to advance preclinical programs without financial distress.
The company has deep expertise in peptide therapeutics and hepcidin biology, having already brought MIMRYLO through FDA approval, which de-risks the mechanism for PN-8047.
▼ Bear Case4
PN-8047 is at the earliest stage of development (preclinical) with no disclosed IND timeline, no clinical data, and no guarantee it will ever enter human trials.
Developing an oral version of a peptide drug is technically challenging; oral bioavailability of peptides is notoriously difficult to achieve.
The polycythemia vera market is already served by MIMRYLO (injectable) and other therapies, and an oral hepcidin mimetic would face a long, expensive clinical development path with high attrition risk.
PN-8047 is one of several early preclinical programs (alongside PN-477 and PN-458) and is unlikely to contribute to Protagonist's valuation for years, if ever.

Upcoming Catalysts

  • No near-term catalysts for PN-8047 specifically. The next pipeline catalyst for Protagonist is PN-881 Phase 2b initiation expected in early Q1 2027.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Protagonist Therapeutics, Inc 8-K PTGX ·Originating report

Sources · 5

Hover a chip for the title
1 usatoday.com2 markets.financialcontent.com3 sec.gov4 seekingalpha.com5 seekingalpha.com